| 1998 | Telomerase Activity and Telomere Lengths in Various Cell Lines: Changes of Telomerase Activity Can Be Another Method for Chemosensitivity Evaluation | INTERNATIONAL JOURNAL OF ONCOLOGY |
| 2013 | Telomerase- and angiogenesis-related gene responses to irradiation in human umbilical vein endothelial cells | INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE |
| 2019 | Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma
| CANCER RESEARCH AND TREATMENT |
| 2010 | The clinical outcome of chemotherapy-induced amenorrhea in premenopausal young patients with breast cancer with long-term follow-up | ANNALS OF SURGICAL ONCOLOGY |
| 2010 | The clinical significance of ascitic fluid CEA in advanced gastric cancer with ascites | JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY |
| 2015 | The Clinicopathologic Features and Prognostic Impact of ALK Positivity in Patients with Resected Gastric Cancer | ANNALS OF SURGICAL ONCOLOGY |
| 2008 | The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2014 | The effect of disintegrin-metalloproteinase ADAM9 in gastric cancer progression. | MOLECULAR CANCER THERAPEUTICS |
| 2009 | The effect of spleen-preserving lymphadenectomy on surgical outcomes of locally advanced proximal gastric cancer | JOURNAL OF SURGICAL ONCOLOGY |
| 2015 | The Impact of Coping Styles on Psychological Distress and Quality of Life in Korean Patients with Cancer
| Korean Journal of Psycho-Oncology (정신종양학회지) |
| 2021 | The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer
| NATURE |
| 2004 | The pattern of gene copy number changes in bilateral breast cancer surveyed by cDNA microarray-based comparative genomic hybridization. | INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE |
| 2018 | The prognostic value of volume-based parameters using<sup>18</sup>F-FDG PET/CT in gastric cancer according to HER2 status | GASTRIC CANCER |
| 2001 | The significance of granzyme B expression in patients with angiocentric lymphoma of the head and neck | CANCER |
| 2013 | Therapeutic Strategies for Well-differentiated Papillary Mesothelioma of the Peritoneum
| JAPANESE JOURNAL OF CLINICAL ONCOLOGY |
| 2000 | Tissue urokinase-type plasminogen activator receptor levels in breast cancer | International Journal of Molecular Medicine |
| 2020 | Transcriptome analysis of iBET-151, a BET inhibitor alone and in combination with paclitaxel in gastric cancer cells
| Genomics & Informatics |
| 2023 | Trastuzumab Combined With Ramucirumab and Paclitaxel in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Advanced Gastric or Gastroesophageal Junction Cancer | JOURNAL OF CLINICAL ONCOLOGY |
| 2022 | Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01) | JOURNAL OF CLINICAL ONCOLOGY |
| 2023 | Trastuzumab Deruxtecan in Anti-Human Epidermal Growth Factor Receptor 2 Treatment-Naive Patients With Human Epidermal Growth Factor Receptor 2-Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial
| JOURNAL OF CLINICAL ONCOLOGY |
| 2020 | Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer | NEW ENGLAND JOURNAL OF MEDICINE |
| 2017 | Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study | LANCET ONCOLOGY |
| 2010 | Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. | LANCET |
| 2002 | Treatment of advanced gastric cancer by palliative gastrectomy, cytoreductive therapy and postoperative intraperitoneal chemotherapy. | BRITISH JOURNAL OF SURGERY |
| 2011 | Treatment of recurrent hepatocellular carcinoma after liver transplantation | ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY |
| 2009 | Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea
| CANCER RESEARCH AND TREATMENT |
| 2022 | Tropomyosin-Related Kinase Fusions in Gastrointestinal Stromal Tumors
| CANCERS |
| 2004 | Tumor-specific gene therapy for uterine cervical cancer using MN/CA9-directed replication-competent adenovirus | CANCER GENE THERAPY |
| 2010 | Two dosages of oral fluoropyrimidine S-1 of 35 and 40 mg/m2 bid: comparison of the pharmacokinetic profiles in Korean patients with advanced gastric cancer
| JAPANESE JOURNAL OF CLINICAL ONCOLOGY |
| 2008 | Variation of the 3' telomeric overhang lengths in human cells | CANCER LETTERS |
| 2020 | Waun Ki Hong, MD, D.M.Sc (Hon) (1942-2019): A Mentor Who Left Behind a Legacy for Generations to Come
| YONSEI MEDICAL JOURNAL |
| 2007 | Whole genome analysis for liver metastasis gene signatures in colorectal cancer | INTERNATIONAL JOURNAL OF CANCER |
| 1996 | 골육종환자에서 다방면 복합요법의 효과 및 P-Glycoprotein 과다발현의 임상적 의의
| Journal of the Korean Cancer Association(대한암학회지) |
| 1997 | 국소 진행 유방암의 신보조 화학요법 후 잔류 암 평가에 었어서 유방촬영술의 역할: 임상적 평가와의 비교
| Journal of the Korean Radiologist Society (대한방사선의학회지) |
| 2004 | 국소 진행된 직장암의 수술 전 화학방사선 요법 치료 후 종양반응 분석: 종양체적 변화와 병리조직학적 병기하강과의 상관관계 분석
| Journal of the Korean Society of Coloproctology |
| 2000 | 국소진행성 직장암에서 수술 전 방사선 및 항암화학 동시요법의 효과
| Journal of the Korean Society for Therapeutic Radiology and Oncology |
| 1998 | 근골격계 종양에서 Telomerase 활성도 연구 | Journal of Korean Orthopaedic Research Society (대한정형외과연구학회지) |
| 1995 | 근치적 절제술이 시행된 대장 및 직장암에서 c-erbB-2의 표현과 임상적 의의
| Journal of the Korean Cancer Association(대한암학회지) |
| 1999 | 다형성교모세포종 세포주와 종양조직에서 Midkine 발현
| Journal of the Korean Cancer Association (대한암학회지) |
| 1997 | 생물학적 치료 목표로서 위암에서 Midkine 발현의 탐색 | Journal of the Korean Cancer Association (대한암학회지) |
| 1996 | 소세포 폐암에서 CAV 및 EP 교대항암약물요법의 치료성적과 국한성병기에서 조기 방사선치료의 병용효과
| Journal of the Korean Cancer Association(대한암학회지) |
| 1997 | 신장에 전이된 간세포암 1예 | Journal of the Korean Cancer Association (대한암학회지) |
| 1996 | 악성 종양 환자에서 새로운 Anthracycline 유도체: DA-125의 제1상 및 약동학 연구
| Journal of the Korean Cancer Association(대한암학회지) |
| 1998 | 암 발생 과정에서 유방암 세포의 TGF-β에 대한 저항성 획득과 제1형 및 제2형 TGF-β 수용체의 유전자 변화에 관한 연구
| Journal of the Korean Cancer Association (대한암학회지) |
| 2001 | 암 치료에 있어 혈관신생 연구
| Korean journal of Endocrine Surgery (대한내분비외과학회지) |
| 1997 | 원발성 유방림프종 : 임상 및 유방 촬영 소견
| Journal of the Korean Radiologist Society (대한방사선의학회지) |
| 1997 | 위암 세포주에 대한 성장인자 억제제와 항 전이제의 항 종양 효과에 관한 연구
| Journal of the Korean Cancer Association (대한암학회지) |
| 1997 | 위암 조직에서 Midkine 유전자 발현
| Journal of the Korean Cancer Association (대한암학회지) |
| 1997 | 위암 진행 표지자로서 혈액내 Intercellular Adhesion Molecule-1 (ICAM-1)과 Vascular Cell Adhesion Molecule-1 (VCAM-1)의 동시 발현 | Journal of the Korean Cancer Association (대한암학회지) |
| 1997 | 위암 환자의 혈액 및 조직에서 Urokinase-type Plasminogen Activator 발현의 임상적 의의 | Journal of the Korean Cancer Association (대한암학회지) |
| 1996 | 위암에서 Collagen-4 및 Type-4 Collagenase의 발현과 예후인자로서 임상적 응용
| Korean Journal of Gastroenterology |
| 2000 | 위암에서 ex vivo Model 을 이용한 MMP - 9 에 대한 Gabexate Mesylate IC50의 응용 : 예후인자 및 치료대상 선정기준
| Journal of the Korean Cancer Association (대한암학회지) |
| 1996 | 위암에서 침윤과 전이의 새로운 생물학적 표지자로서 urokinase-type plasminogen activator(uPA)의 발현
| Journal of the Korean Cancer Association(대한암학회지) |
| 1995 | 위암환자의 종양지표지자로서 혈액내 c-erbB-2 종양단백의 탐색
| Journal of the Korean Cancer Association(대한암학회지) |
| 2000 | 유방암 조직에서 Urokinase - type Plasrninogen Activator Receptor 발현의 임상적 의의
| Journal of the Korean Cancer Association (대한암학회지) |
| 1997 | 유방암 진행에 따른 Telomerase Activity 발현 증가
| Journal of the Korean Cancer Association (대한암학회지) |
| 1997 | 유방암 환자에서 발생한 크립토콕쿠스 수막염 1예
| CANCER RESEARCH AND TREATMENT |
| 1998 | 유방암 환자에서 종양 표지자로서 혈액내 TGF-β1의 분포에 관한 연구
| Journal of the Korean Cancer Association (대한암학회지) |
| 1999 | 유방암 환자의 혈액 및 암조직에서 생물학적 치료의 Target으로서 Urokinase-type Plasminogen Activator(uPA), uPA Receptor, Plasminogen Activator Inhibitor-1의 발현.
| Journal of the Korean Cancer Association (대한암학회지) |
| 1996 | 유방암에서 Matrix-metalloproteinase-9(MMP-9)의 발현
| Journal of the Korean Cancer Association(대한암학회지) |
